One Health Ventures’ (OHV) is an early stage company, which has developed a proprietary, recombinant, genetic toxoid vaccine candidate against epsilon toxin (ETX), which can be cultured in E.coli, as a treatment for both animals and humans. The vaccine has been successfully trialed in mice, rabbits and sheep and the next step is to seek approval for and then to carry out a Phase 1 trial.
ETX is produced from a common bacteria Clostridium perfringens Types B/D and causes a fatal disease, enterotoxaemia, principally in sheep and goats.
Over the past 7 years, ETX has also been implicated as the trigger for Multiple Sclerosis (MS), which affects about 2.5 million people worldwide and for which there is currently no cure or human vaccine. Significant levels of ETX, antibodies to ETX and the relevant bacterial strains have all been found in MS patients and to a lesser extent in controls.
OHV is seeking a commercial partner(s) either to licence or enter into a joint venture(s) in order to take this project forward.
The website is www.onehealthventures.com